Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I

Abstract

Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as possible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 receptors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic patients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to clozapine. For patients who do respond, there is a wide (>ten-fold) range in optimal doses. Refractoriness or low sensitivity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozapine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is lost.

Neurophysiological Changes Induced by Chronic <em>Toxoplasma gondii</em> Infection

“…Of significant note, very specific subtle behavioral changes can be associated with global modifications in neurotransmission. For example, common schizophrenia medications inhibit dopamine D2 receptors; these act globally, affecting catecholamine signaling on neurons expressing the receptors yet these are beneficial, specifically effecting the positive symptoms of schizophrenia although some side-effects are observed [104]. This suggests that the relationship between neurophysiological changes and behavior is not linear.…”

<b>New drugs for the treatment of agitation in schizophrenia: a systematic review and meta-analysis of inhaled loxapine and infused sodium nitroprusside

“…With the growth and development of the pharmaceutical industry, approximately 200 novel drugs are being studied, with approximately 1/3 of them having a primary indication for schizophrenia (PHRMA, 2014;Chien & Yip, 2013). Although gradual advances in the development of these drugs have occurred, impairment of the efficacy of the therapies as well as adverse events remains (Miller, 2009;Chien & Yip, 2013).…”

Predictors of Concomitant Use of Antipsychotics and Stimulants and Its Impact on Stimulant Persistence in Pediatric Attention Deficit Hyperactivity Disorder

“…6,18 They are approved by the U.S. Food and Drug Administration (FDA) in children for the treatment of bipolar I disorder (mania or mixed), schizophrenia, and irritability associated with autistic disorder. [19][20][21] However, children are being prescribed antipsychotics to control behavioral symptoms of ADHD or comorbid aggression and for other nonapproved indications.…”